RankAlpha logo
Back to Rankings

ELAN

Elanco Animal HealthA
NYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
The Q2 print showed broad operating momentum: revenue rose 10% year over year, organic constant-currency growth was 8%, and management cited Zenrelia and Credelio Quattro as major growth drivers. Raised full-year guidance and improving leverage support a constructive operating thesis.
Posture
Constructive
Lead driver
Sentiment
What changed
3 setup hits (3d) with net bullish as of 2026-09-08.
What can break
Analyst target counts, estimate revisions, options data, short interest, and social coverage are unavailable; direct animal-health peers improve context but differ in scale, product mix, and geographic exposure.
Momentum
26
Value
62
Sentiment
78
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $25.99 · Bull $31.46 · Bear $21.00Analysis 2026-08-25; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-25 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-09-09

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions

Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Bullish
Target $31.46
Why
Momentum26 · Δ7d +7.3
Value62 · Δ7d 0.0
Sentiment78 · Δ7d +6.5
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.

Confirming evidence

  • • 3 setup hits (3d) with net bullish as of 2026-09-08.
  • • Sentiment remains the lead driver in the composite, 7D delta +6.5.

Contradictions & invalidation

  • • Analyst target counts, estimate revisions, options data, short interest, and social coverage are unavailable; direct animal-health peers improve context but differ in scale, product mix, and geographic exposure.
  • • Befrena supply constraints and capacity expansion could limit commercial uptake.
  • • The thesis depends on sustained innovation-product adoption, competitive pricing, and successful Befrena capacity expansion.

Catalyst clock

2026-08-05

Q2 beat and raised FY2026 outlook

Lead driver: Sentiment · See AI snapshot
Momentum
26
9% active weight
Current posture
7d trendImproving
Δ7d
+7.3
Δ21d
-0.8
Value
62
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+1.0
Sentiment
78
62% active weight
Current posture
7d trendImproving
Δ7d
+6.5
Δ21d
-13.4
Why this grade

Composite grade A. Momentum 25.7 / Value 61.7 / Sentiment 78.3

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-25. Scenario method

B+
Bull case
25%
Probability
Target price
$31.46
Analysis reference price unavailable
Analysis 2026-08-25 · RankAlpha Sentiment Codex
Most likely
B
Base case
55%
Probability
Target price
$25.99
Analysis reference price unavailable
Analysis 2026-08-25 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$21.00
Analysis reference price unavailable
Analysis 2026-08-25 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$11.8B
Beta
1.87
Shares Out
499.62M
P/E (TTM)
321.8
P/S (TTM)
2.49
P/FCF (TTM)
31.64
Rev YoY
+10.2%
EPS YoY
+380.6%
Gross Margin
+44.3%
Op Margin
+6.6%
Net Debt
$3.6B
Current Ratio
2.05
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data